论文部分内容阅读
目的探讨血清基质金属蛋白酶-9(MMP-9)与系统性红斑狼疮(SLE)活动程度的关系和意义。方法采用双抗体夹心酶联免疫吸附测定法,检测30名健康人和36例SLE患者血清MMP-9水平,以分析其与SLE活动性变化关系。结果SLE患者血清MMP-9水平[(108±113)ng/ml]明显低于正常对照组[(352±115)ng/ml],P<0.001;糖皮质激素治疗后血清MMP-9水平[(246±196)ng/ml]与治疗前水平[(114±92)ng/ml]相比,差异有显著性意义(P<0.05);SLE患者活动期血清MMP-9水平[(72±66)ng/ml]低于非活动期[(166±146)ng/ml],P<0.05;SLEDAI>8分组[(80±72)ng/ml]低于SLEDAI≤8分组[(152±150)ng/ml],P<0.05;蛋白尿组[(82±20)ng/ml]低于非蛋白尿组[(152±43)ng/ml],P<0.05;关节炎组[(103±126)ng/ml]与非关节炎组[(117±89)ng/ml]之间差异无显著性,P>0.05。结论MMP-9可能与SLE的发病相关,血清MMP-9可作为反映SLE活动程度、肾脏损害及疾病进展或改善的一项指标。
Objective To investigate the relationship between serum matrix metalloproteinase-9 (MMP-9) and systemic lupus erythematosus (SLE) activity. Methods The serum levels of MMP-9 in 30 healthy people and 36 SLE patients were detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA), and their relationship with SLE activity was analyzed. Results Serum levels of MMP-9 in SLE patients [(108 ± 113) ng / ml] were significantly lower than those in controls (352 ± 115) ng / ml, P <0.001; serum levels of MMP-9 after glucocorticoid therapy [ (246 ± 196) ng / ml] was significantly higher than that before treatment [(114 ± 92) ng / ml], P < (80 ± 72) ng / ml] was lower than SLEDAI≤8 group [(152 ± (82 ± 20) ng / ml] in the albuminuria group [(152 ± 43) ng / ml], P <0.05; 103 ± 126) ng / ml] and non-arthritis group [(117 ± 89) ng / ml]. There was no significant difference between the two groups (P> 0.05). Conclusion MMP-9 may be related to the pathogenesis of SLE. Serum MMP-9 may be used as an index to reflect the degree of SLE activity, renal damage and disease progression or improvement.